- 11 Feb 2022
- ICICIdirect Research
HEALTHCARE GLOBAL Q3 CONTINUES TURNAROUND MOMENTUM
HCG - 419 Change: -4.35 (-1.03 %)News: Healthcare Global’s (HCG) revenues grew 30.7% YoY to Rs.358.1 crore driven by 30.8% YoY growth in HCG centers and 28.5% YoY growth in Milann centers. EBITDA margins improved 338 bps YoY to 17.3% while EBITDA grew 62.4% YoY to Rs.61.9 crore. The company has reported exceptional loss of Rs.45.5 crore mainly on account of impairment charges for greenfield project in Gurugram. Adjusted net profit for the quarter was at Rs.3.3 crore against loss of Rs.20.7 crore in Q3FY21.
Views: HCG posted good numbers in Q3 on expected lines amid strong yearly growth in footfalls and several centers witnessing turnaround in EBITDA. HCG, with its integrated, one-stop-solution and focused model, is well poised to capture the growing potential with pan- India focus on cancer therapy. However, weaker return ratio profile still remains a key concern for the stock.
Impact: Positive